---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-029009"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:58:28.281490+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Treace Medical Q4 revenue $68.7M (+10% YoY); net loss narrows to $0.5M; guides FY25 rev $224-230M

## Summary
- Q4 revenue $68.7M (+10% YoY); net loss ($0.5M) vs ($6.3M) in Q4 2023; adj. EBITDA $11.1M (322% improvement).
- Full-year 2024 revenue $209.4M (+12% YoY); net loss ($55.7M) vs ($49.5M); adj. EBITDA loss narrowed to ($11.0M) from ($24.4M).
- FY2025 revenue guidance $224M-$230M (7-10% growth); expects breakeven adj. EBITDA for full year.
- Entry into osteotomy market with Nanoplasty and Percuplasty 3D bunion systems; 280 new active surgeons added in 2024.
- Cash $75.7M plus $26M revolver access; patent portfolio 97 granted, 88 pending.

## SEC filing metadata
- accession: 0000950170-25-029009
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000095017025029009/0000950170-25-029009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000095017025029009/tmci-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-029009
- JSON: https://secwatch.observer/filing/0000950170-25-029009.json
- Plain text: https://secwatch.observer/filing/0000950170-25-029009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.